A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma.
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Noscapine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Cougar Biotechnology
- 06 Oct 2016 Status changed from completed to discontinued.
- 15 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 15 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.